HRP20110763T1 - Makrolidni konjugati s protuupalnom aktivnošću - Google Patents
Makrolidni konjugati s protuupalnom aktivnošću Download PDFInfo
- Publication number
- HRP20110763T1 HRP20110763T1 HR20110763T HRP20110763T HRP20110763T1 HR P20110763 T1 HRP20110763 T1 HR P20110763T1 HR 20110763 T HR20110763 T HR 20110763T HR P20110763 T HRP20110763 T HR P20110763T HR P20110763 T1 HRP20110763 T1 HR P20110763T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- solvate
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Spoj, naznačen time što ima strukturuili njegova farmaceutski prihvatljiva sol ili solvat. Patent sadrži još 18 patentnih zahtjeva.
Claims (19)
1. Spoj, naznačen time što ima strukturu
[image]
ili njegova farmaceutski prihvatljiva sol ili solvat.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ima strukturu
[image]
ili njegova farmaceutski prihvatljiva sol.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ima strukturu
[image]
.
4. Farmaceutski pripravak naznačen time što sadrži spoj, ili njegovu farmaceutski prihvatljivu sol ili solvat, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, kao i farmaceutski prihvatljiv razrjeđivač ili podlogu.
5. Spoj, ili njegova farmaceutski prihvatljiva sol ili solvat, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je namijenjen upotrebi u medicinskoj terapiji.
6. Spoj, ili njegova farmaceutski prihvatljiva sol ili solvat, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je namijenjen upotrebi u liječenju astme.
7. Spoj, ili njegova farmaceutski prihvatljiva sol ili solvat, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je namijenjen upotrebi u liječenju kronične opstruktivne plućne bolesti.
8. Spoj, ili njegova farmaceutski prihvatljiva sol ili solvat, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je namijenjen upotrebi u liječenju upalne bolesti crijeva.
9. Spoj, ili njegova farmaceutski prihvatljiva sol ili solvat, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je namijenjen upotrebi u liječenju psorijaze.
10. Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3 u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time što je ili je povezana s nepoželjnim upalnim imunosnim odgovorom, te svim bolestima i stanjima uzrokovanim ili povezanim s prekomjernim izlučivanjem TNF-α i IL-1.
11. Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje upalnih stanja i imunosnih ili anafilaktičkih poremećaja povezanih s infiltracijom leukocita u upaljeno tkivo.
12. Upotreba u skladu s patentnim zahtjevom 11, naznačena time što se upalna stanja i imunosne poremećaje bira iz skupine koju čine astma, sindrom dišnog distresa kod odraslih, kronična opstruktivna plućna bolest, upalna stanja crijeva, Crohnova bolest, bronhitis i cistična fibroza.
13. Upotreba u skladu s patentnim zahtjevom 11, naznačena time što se navedena upalna stanja i imunosne poremećaje bira iz skupine koju čine upalna stanja ili imunosni poremećaji pluća, zglobova, očiju, crijeva, kože i srca.
14. Upotreba u skladu s patentnim zahtjevom 11, naznačena time što se navedena upalna stanja i imunosne poremećaje bira iz skupine koju čine astma, sindrom dišnog distresa kod odraslih, bronhitis, cistična fibroza, reumatoidni artritis, reumatoidni spondilitis, osteoartritis, gihtični artritis, uveitis, konjunktivitis, upalna stanja crijeva, Crohnova bolest, ulcerozni kolitis, distalni proktitis, psorijaza, ekzem, dermatitis, oštećenje nakon koronarnog infarkta, kronična upala, endotoksinski šok, te poremećaji proliferacije glatkih mišića.
15. Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3 u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time što je ili je povezana s prekomjernom nereguliranom proizvodnjom citokina ili posrednika upale.
16. Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje astme.
17. Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje kronične opstruktivne plućne bolesti.
18. Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje upalne bolesti crijeva.
19. Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje psorijaze.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HR20030324A HRP20030324A2 (en) | 2003-04-24 | 2003-04-24 | Compounds of antiinflammatory effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110763T1 true HRP20110763T1 (hr) | 2011-11-30 |
Family
ID=33307078
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20030324A HRP20030324A2 (en) | 2003-04-24 | 2003-04-24 | Compounds of antiinflammatory effect |
| HR20090551T HRP20090551T1 (hr) | 2003-04-24 | 2004-04-23 | Makrolidni konjugati s protuupalnom aktivnošću |
| HR20110763T HRP20110763T1 (hr) | 2003-04-24 | 2011-10-19 | Makrolidni konjugati s protuupalnom aktivnošću |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20030324A HRP20030324A2 (en) | 2003-04-24 | 2003-04-24 | Compounds of antiinflammatory effect |
| HR20090551T HRP20090551T1 (hr) | 2003-04-24 | 2004-04-23 | Makrolidni konjugati s protuupalnom aktivnošću |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7579334B2 (hr) |
| EP (2) | EP2070940B1 (hr) |
| JP (1) | JP4613366B2 (hr) |
| KR (1) | KR101107336B1 (hr) |
| CN (1) | CN100393741C (hr) |
| AR (1) | AR044083A1 (hr) |
| AT (1) | ATE518876T1 (hr) |
| AU (1) | AU2004232546B2 (hr) |
| BR (1) | BRPI0410490A (hr) |
| CA (1) | CA2523081C (hr) |
| CL (1) | CL2004000872A1 (hr) |
| CY (2) | CY1109491T1 (hr) |
| DE (1) | DE602004022047D1 (hr) |
| DK (2) | DK1633771T3 (hr) |
| ES (2) | ES2370371T3 (hr) |
| HR (3) | HRP20030324A2 (hr) |
| IS (2) | IS2736B (hr) |
| ME (1) | MEP34708A (hr) |
| MX (1) | MXPA05011359A (hr) |
| NO (2) | NO333909B1 (hr) |
| PL (2) | PL1633771T3 (hr) |
| PT (2) | PT1633771E (hr) |
| RS (1) | RS52621B (hr) |
| RU (1) | RU2355699C2 (hr) |
| SI (2) | SI1633771T1 (hr) |
| WO (1) | WO2004094449A1 (hr) |
| ZA (1) | ZA200508388B (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR043050A1 (es) | 2002-09-26 | 2005-07-13 | Rib X Pharmaceuticals Inc | Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos |
| HRP20030324A2 (en) | 2003-04-24 | 2005-02-28 | Pliva-Istra�iva�ki institut d.o.o. | Compounds of antiinflammatory effect |
| US8202843B2 (en) | 2004-02-27 | 2012-06-19 | Rib-X Pharmaceuticals, Inc. | Macrocyclic compounds and methods of making and using the same |
| EP1778292A2 (en) * | 2004-08-12 | 2007-05-02 | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. | Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract |
| US20060183696A1 (en) * | 2004-08-12 | 2006-08-17 | Pliva-Istrazivacki Institut D.O.O. | Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract |
| AU2005298312A1 (en) * | 2004-10-27 | 2006-05-04 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Conjugates with anti-inflammatory activity |
| AU2006327181A1 (en) * | 2005-12-22 | 2007-06-28 | Hydra Biosciences, Inc. | TRPA1 inhibitors for treating pain |
| WO2007093840A2 (en) * | 2006-02-15 | 2007-08-23 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract |
| CA2717456A1 (en) * | 2008-03-05 | 2009-09-11 | Panacea Biotec Limited | Modified release pharmaceutical compositions comprising mycophenolate and processes thereof |
| CN102838660B (zh) * | 2011-06-23 | 2016-11-02 | 上海市第一人民医院 | 一种抑制炎症免疫反应的小肽及其应用 |
| WO2014115167A2 (en) * | 2013-01-23 | 2014-07-31 | Sphaera Pharma Pvt. Ltd. | Novel compounds of 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion |
| US20140256666A1 (en) * | 2013-03-08 | 2014-09-11 | Allergan, Inc. | Antibiotic conjugates with nonsteroidal anti-inflammatory drugs |
| JP2016510753A (ja) * | 2013-03-08 | 2016-04-11 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ステロイド薬と結合した抗生物質共役体 |
| WO2014138437A1 (en) | 2013-03-08 | 2014-09-12 | Allergan, Inc. | Steroid conjugates |
| WO2014138350A1 (en) | 2013-03-08 | 2014-09-12 | Allergan, Inc. | Antibiotic conjugates directly linked with steroid drugs |
| CN106714770B (zh) | 2014-07-23 | 2024-04-19 | 斯法尔制药私人有限公司 | 羟基类固醇化合物、其中间体、制备方法、组合物及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3779221D1 (de) | 1986-08-19 | 1992-06-25 | Genentech Inc | Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen. |
| DE3860503D1 (de) * | 1987-09-03 | 1990-10-04 | Pliva Pharm & Chem Works | 10-dihydro-10-deoxo-11-azaerythronolid-a-verbindungen,verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung in arzneimitteln und in deren herstellung. |
| SE9100341D0 (sv) | 1991-02-04 | 1991-02-04 | Astra Ab | Novel steroids |
| SE9100342D0 (sv) | 1991-02-04 | 1991-02-04 | Astra Ab | Novel steroid esters |
| GB9225923D0 (en) | 1992-12-11 | 1993-02-03 | Rhone Poulenc Rorer Ltd | New compositions of matter |
| FI953130A0 (fi) | 1992-12-24 | 1995-06-22 | Rhone Poulenc Rorer Ltd | Uudet steroidit |
| CN1159757A (zh) | 1994-08-12 | 1997-09-17 | 大正制药株式会社 | 抑制白细胞介素5产生的抑制剂 |
| EP0775489A4 (en) | 1994-08-12 | 1998-05-06 | Taisho Pharmaceutical Co Ltd | INTERLEUKIN-5 PRODUCTION INHIBITOR |
| DE19616573C2 (de) | 1996-04-25 | 1999-03-04 | Pari Gmbh | Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase |
| JP3530004B2 (ja) | 1998-02-06 | 2004-05-24 | 株式会社日立ユニシアオートモティブ | 吸入式投薬器 |
| EP1126838A4 (en) | 1998-10-30 | 2005-02-16 | Nitromed Inc | NITROSIS AND NITROSYAL NON-STEROID ANTI-INFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE |
| IT1306205B1 (it) | 1999-01-15 | 2001-05-30 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria. |
| HRP20000310A2 (en) | 2000-05-17 | 2002-02-28 | Pliva Farmaceutska Ind Dioniko | New dibenzoazulene compounds as tumor necrosis factor inhibitors |
| FI110835B (fi) | 2000-07-11 | 2003-03-31 | Radiolinja Ab | Menetelmä palvelunumeropuhelun tarjoamiseksi matkaviestintilaajalle ennalta määrätyllä taksalla |
| HRP20010018A2 (en) | 2001-01-09 | 2002-12-31 | Pliva D D | Novel anti-inflammatory compounds |
| US20040186063A1 (en) | 2002-02-15 | 2004-09-23 | Hans-Jurgen Gutke | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| WO2003070174A2 (en) | 2002-02-15 | 2003-08-28 | Sympore Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| HRP20040849A2 (en) | 2002-02-15 | 2005-08-31 | Synovo Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| ATE429441T1 (de) | 2002-07-08 | 2009-05-15 | Glaxosmithkline Zagreb | Hybridmoleküle von makroliden mit steroidalen/nicht-steroidalen antientzündlich aktiven molekülen |
| JP4790263B2 (ja) | 2002-07-08 | 2011-10-12 | グラクソ グループ リミテッド | 炎症性の疾患および病態を治療する新規な化合物、組成物および方法 |
| AU2003255849A1 (en) | 2002-07-08 | 2004-01-23 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
| HRP20030324A2 (en) | 2003-04-24 | 2005-02-28 | Pliva-Istra�iva�ki institut d.o.o. | Compounds of antiinflammatory effect |
-
2003
- 2003-04-24 HR HR20030324A patent/HRP20030324A2/hr not_active Application Discontinuation
-
2004
- 2004-04-22 US US10/830,858 patent/US7579334B2/en not_active Expired - Fee Related
- 2004-04-23 DK DK04729157T patent/DK1633771T3/da active
- 2004-04-23 WO PCT/IB2004/001235 patent/WO2004094449A1/en active Application Filing
- 2004-04-23 PT PT04729157T patent/PT1633771E/pt unknown
- 2004-04-23 RS YU20050873A patent/RS52621B/en unknown
- 2004-04-23 CA CA2523081A patent/CA2523081C/en not_active Expired - Lifetime
- 2004-04-23 AR ARP040101400A patent/AR044083A1/es unknown
- 2004-04-23 EP EP09075145A patent/EP2070940B1/en not_active Expired - Lifetime
- 2004-04-23 PT PT09075145T patent/PT2070940E/pt unknown
- 2004-04-23 DK DK09075145.4T patent/DK2070940T3/da active
- 2004-04-23 AU AU2004232546A patent/AU2004232546B2/en not_active Ceased
- 2004-04-23 ES ES09075145T patent/ES2370371T3/es not_active Expired - Lifetime
- 2004-04-23 CL CL200400872A patent/CL2004000872A1/es unknown
- 2004-04-23 MX MXPA05011359A patent/MXPA05011359A/es active IP Right Grant
- 2004-04-23 JP JP2006506511A patent/JP4613366B2/ja not_active Expired - Fee Related
- 2004-04-23 PL PL04729157T patent/PL1633771T3/pl unknown
- 2004-04-23 PL PL09075145T patent/PL2070940T3/pl unknown
- 2004-04-23 ES ES04729157T patent/ES2330109T3/es not_active Expired - Lifetime
- 2004-04-23 AT AT09075145T patent/ATE518876T1/de active
- 2004-04-23 DE DE602004022047T patent/DE602004022047D1/de not_active Expired - Lifetime
- 2004-04-23 ME MEP-347/08A patent/MEP34708A/xx unknown
- 2004-04-23 SI SI200431253T patent/SI1633771T1/sl unknown
- 2004-04-23 HR HR20090551T patent/HRP20090551T1/hr unknown
- 2004-04-23 SI SI200431768T patent/SI2070940T1/sl unknown
- 2004-04-23 CN CNB2004800110487A patent/CN100393741C/zh not_active Expired - Fee Related
- 2004-04-23 BR BRPI0410490-0A patent/BRPI0410490A/pt not_active Application Discontinuation
- 2004-04-23 KR KR1020057020252A patent/KR101107336B1/ko not_active Expired - Fee Related
- 2004-04-23 RU RU2005131937/04A patent/RU2355699C2/ru not_active IP Right Cessation
- 2004-04-23 EP EP04729157A patent/EP1633771B1/en not_active Expired - Lifetime
-
2005
- 2005-10-17 ZA ZA200508388A patent/ZA200508388B/xx unknown
- 2005-11-22 IS IS8141A patent/IS2736B/is unknown
- 2005-11-23 NO NO20055535A patent/NO333909B1/no not_active IP Right Cessation
-
2009
- 2009-10-14 CY CY20091101070T patent/CY1109491T1/el unknown
-
2010
- 2010-12-29 IS IS8941A patent/IS8941A/is unknown
-
2011
- 2011-10-19 HR HR20110763T patent/HRP20110763T1/hr unknown
- 2011-10-25 CY CY20111101008T patent/CY1111978T1/el unknown
-
2013
- 2013-06-28 NO NO20130898A patent/NO335552B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110763T1 (hr) | Makrolidni konjugati s protuupalnom aktivnošću | |
| JP2005531584A5 (hr) | ||
| JP2005529890A5 (hr) | ||
| JP2009531292A5 (hr) | ||
| JP2009510044A5 (hr) | ||
| JP2018513107A5 (hr) | ||
| EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
| JP2005523338A5 (hr) | ||
| JP2017528507A5 (hr) | ||
| RU2008137086A (ru) | Борсодержащие малые молекулы в качестве противовоспалительных средств | |
| HRP20100359T1 (hr) | Specifični glukokortikoidni spoj s protuupalnom aktivnošću | |
| RU2017114346A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| RU2014106611A (ru) | Производные гетероциклических амидов в качестве антагонистов р2х7 рецептора | |
| CN114450275B (zh) | 杂芳基氨基吡啶醇衍生物以及包含其为活性成分的用于预防或治疗自身免疫性疾病的药物组合物 | |
| JP2006522006A5 (hr) | ||
| JP2008526950A5 (hr) | ||
| CN106061478A (zh) | 含有烷基醚衍生物或其盐的神经损伤后的康复效果促进剂 | |
| HRP20200394T1 (hr) | Smjesa masnih kiselina (gmk, grupa masnih kiselina) za primjenu u liječenju inflamatornih patologija | |
| ES2736155T3 (es) | Comprimidos de otilonio por compresión directa | |
| JP2013544244A5 (hr) | ||
| HRP20240697T1 (hr) | Derivati n-metil, n-(6-(metoksi)piridazin-3-il) amina kao modulatori autotaksina (atx) za liječenje upalnih bolesti dišnih puteva ili fibroznih bolesti | |
| JP2017080507A5 (hr) | ||
| RU2013127793A (ru) | Противовоспалительные композиции | |
| JP2015535270A5 (hr) | ||
| HRP20240831T1 (hr) | Derivati 1-(6-(metoksi)piridazin-3-il)ciklopropan-1-karboksamida kao modulatori autotaksina (atx) za liječenje upalnih bolesti dišnih puteva |